Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients

Chronic migraine (CM) is a highly disabling primary headache. Botulinum toxin (onabotulinumtoxinA) is effective for treatment of CM, with ~ 50% of patients responding after 24 weeks. A response predictor would prevent unnecessary treatments. Inhibiting calcitonin gene related peptide (CGRP) release...

Descripción completa

Detalles Bibliográficos
Autores principales: Eren, Ozan E., Gaul, Charly, Peikert, Andreas, Gendolla, Astrid, Ruscheweyh, Ruth, Straube, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347633/
https://www.ncbi.nlm.nih.gov/pubmed/32647152
http://dx.doi.org/10.1038/s41598-020-68149-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347633/
https://www.ncbi.nlm.nih.gov/pubmed/32647152
http://dx.doi.org/10.1038/s41598-020-68149-1

Ejemplares similares